Global and United States Adeno-Associated Virus (AAV) Gene Therapy Market Size, Analysis and Forecast 2023-2030

The Global AAV gene therapy market saw a revenue of US$ 1.637 billion in 2022 and is expected to reach US$ 2.957 billion by 2029 at a CAGR of 8.8%.

To Know more about this report (Description, TOC and List of Tables and Figures) — Global AAV gene therapy market

This growth is driven by several factors, including:

• Rising awareness of gene therapy: Advancements in gene therapy have increased public and medical professional interest in its potential to treat genetic and acquired diseases.
• Increasing approvals of AAV-based therapies: Regulatory approvals for AAV-based treatments like Luxturna for retinal dystrophy and Zolgensma for spinal muscular atrophy have created momentum for the market.
• Expanding pipeline of AAV therapies: A strong pipeline of AAV-based therapies in development for various diseases like hemophilia, Parkinson's disease, and cancer offers promise for future market growth.
• Technological advancements: Improvements in AAV capsid engineering and manufacturing processes are enhancing the efficacy and efficiency of AAV-based therapies, making them more cost-effective and accessible.

Key Players:

The AAV gene therapy market is characterized by a mix of established pharmaceutical companies and emerging biotech startups. Some of the key players include:

1. Creative Biolabs
2. Affinia Therapeutics
3. Spark Therapeutics
4. AGC Biologics
5. StrideBio
6. SIRION Biotech
7. Neurophth Biotechnology
8. Belief BioMed
9. BiBo Biopharma Engineering Co., LTD.
10. Beihai Kangcheng
11. PackGene Biotech
12. Sarepta Therapeutics
13. Carbon BioSciences
14. Kelonia Therapeutics
15. Roche
16. Remedium Bio

Drivers and Opportunities:

• Increasing investment in R&D: Growing investments from venture capitalists and pharmaceutical companies in AAV gene therapy research and development are fueling market expansion.
• Expanding application base: AAV therapies are showing promise in treating a wider range of diseases beyond rare genetic disorders, opening new market avenues.
• Government support: Initiatives from governments worldwide to support orphan drug development and gene therapy research are creating favourable market conditions.

Segmentation by Type:

• Luxturna
• Zolgensma
• Others (includes therapies for hemophilia, Parkinson's disease, etc.)

Segmentation by Application:

1. Central Nervous System Diseases
2. Ocular Diseases
3. Liver-directed Diseases
4. Other Hereditary Diseases

Segmented by Region:

1. North America holds the largest market share due to a well-developed healthcare infrastructure and early adoption of gene therapy technologies.
2. Europe is also a significant market with strong research capabilities and government support for rare disease treatment.
3. The Asia Pacific region is expected to witness rapid growth in the coming years due to a large patient population and increasing healthcare spending.
4. South America and the Middle East and Africa have smaller market shares but present potential for future growth as awareness and affordability improve.

The AAV gene therapy market is poised for significant growth in the coming years, driven by technological advancements, expanding applications, and increasing government and private sector support. Key players will need to focus on developing next-generation AAV vectors, optimizing manufacturing processes, and expanding access to treatment to capitalize on this promising market.